Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Cancer J
Autors principals: Nazha, Aziz, Sekeres, Mikkael A., Komrokji, Rami, Steensma, David P., Kantarjian, Hagop, Roboz, Gail, Fenaux, Pierre, Prebet, Thomas, Azarnia, Nozar, Zbyszewski, Patrick S., Fruchtman, Steven M., Santini, Valeria, Silverman, Lewis R., Platzbecker, Uwe, Garcia-Manero, Guillermo
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2017
Matèries:
Correspondence
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5802598/
https://ncbi.nlm.nih.gov/pubmed/29238044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-017-0018-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars